Bannerbild German Brest Group - Patientinnen

The procedures involved in clinical drug trials

New active substances are required to undergo a multi-stage approval process including efficacy tests before being admitted for the treatment of breast cancer. The German Breast Group designs studies of this kind and implements them in cooperation with clinical investigators.

Media reports on each phase of a trial reflect the current status at a particular point in time and do not necessarily permit any conclusions to be drawn about the efficacy or approval of a new drug.

Prior to the commencement of a breast cancer trial

Before human beings come into contact with a new drug, scientists test the drug for efficacy by performing statutory laboratory testing procedures on cell and tissue cultures and then on animals. Only if these tests produce promising results are researchers allowed to administer the active substance to human beings.

Media reports about promising results at this stage generally point out that the data has been obtained from animal experiments. However, successful trials on animals do not automatically mean that the active substance will receive drug approval. In many cases, researchers abandon drug development projects because tests on human beings do not produce the desired results or have too many negative side effects.

Trial phase I

In this phase, scientists test the active substance on healthy volunteer probands. The purpose of the tests is to provide an indication of the tolerability and possible dosage range of the new drug. In addition, researchers investigate how the active substance is absorbed, distributed, degraded and excreted by the body.

In the case of particularly serious illnesses, such as AIDS or cancer, patients actually suffering from the disease also take part in these early experiments. The number of human beings treated with the drug in trial phases I and II is very low ─ only a few dozen.

Trial phase II

In the second phase of a trial, the active substance is administered to patients suffering from the disease in order to test the efficacy of the drug. In these tests, researchers also identify the most appropriate and tolerable dose. Particular attention is paid to homogeneity within the patient group. Therefore, trial participants have to be very carefully selected in this phase.

Media reports about results in the second phase of a trial often speak of successful tests on a “limited number of patients”. It takes several more years for the new drug to be approved. This is because the lengthiest and most complicated part of the clinical testing procedure is still to come: trial phase III.

Trial phase III

Phase III is the final stage of the trial before approval of the new drug. In this phase of the trial, scientists administer a particular dose of the active substance to hundreds of patients. In order to reflect the wide range of patients seen in routine clinical practice as realistically as possible, the participants in this phase are not selected on the basis of strict criteria.

Drugs intended for use over a long period of time are tested in corresponding long-term trials, which are designed to ensure that the active substance remains effective and tolerable even after prolonged use.

Patients who are not satisfied with the medication they have received so far can be given the new active substance within the context of a clinical trial. All patients must comply with the inclusion criteria and receive treatment at a practice participating in the trial.

Promising test results in phase III are the prerequisite for approval of a new drug therapy. The authorities responsible therefore check the drug registration application and the corresponding data very carefully, which is a time-consuming process.

In this final pre-approval phase, more frequent reports about the drug appear in the media owing to the increased information available. By this time, specialist physicians have already had some experience of treating patients with the drug over the course of the trial. Furthermore, papers about the active substance are published in professional journals and at medical congresses.

Trial phase IV

Following approval of the drug, phase IV trials are intended to provide information about its use on a routine basis. The aim is to find out more about rare negative side effects and the efficacy of the drug in particular patient groups.

News

  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...
  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...
  • 27.09.2018 GBG-Jahrestreffen - Save the Date

    GBG-Jahrestreffen - Save the Date

    Das GBG Jahrestreffen 2019 wird am 14. & 15. März 2019 in Niederrad Frankfurt am Main stattfinden.

    Mehr ...
  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

    Mehr ...
  • 11.09.2018 BCC-Breast Cancer Conference 2019 in Vienna

    BCC-Breast Cancer Conference 2019 in Vienna

    The 16th St. Gallen International Breast Cancer Conference 2019 in Vienna is less than seven months away.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd